Programs Feature Simple Enrollment and Meaningful Financial Assistance
March 8, 2011
Allergan, Inc. is seeking patients who are or will be receiving onabotulinumtoxinA injections for the treatment of cervical dystonia for potential observational study participation.
Eligible patients may receive a patient stipend for their participation.
The CD-PROBE Study is a Multi-center, Prospective, Naturalistic, Observational Registry of Cervical Dystonia and Therapy with Botulinum Toxin type A (onabotulinumtoxinA)
To receive information for participating physician’s in your area please contact the CD-PROBE Study at:
email@example.com, or 866-258-2735